UK and US-based Level Zero Health raises €6.63M to develop the first remote hormone monitoring device

London and San Francisco-based Level Zero Health, a healthtech startup, has secured £5.5M (approximately €6.63M) in pre-seed funding. The company aims to create the world’s largest hormone health dataset to drive advanced insights, research, and personalised care.

The funds will support the company in developing DNA-based sensors for remote and continuous hormone monitoring.

The investment round was led by European VC firm Redalpine. Despite a tough funding environment, the company attracted investment from HAX (SOSV), Entrepreneur First, and industry experts.

What does Level Zero Health offer?

Hormones are vital for regulating bodily functions, but for many years, doctors have only used lab blood tests to measure them. These tests provide a one-time snapshot and require specialised equipment and expertise.

Level Zero Health is transforming this by developing technology for remote and continuous hormone monitoring, offering new insights into our body’s chemistry.

The company’s DNA-based sensors measure hormone levels in interstitial fluid instead of through invasive blood draws. In under a year, the company has made significant progress, validating its sensors across 98 per cent of the human clinical range. 

Founded by Ula Rustamova, a former Palantir tech lead, and Irene Jia, an expert in medical devices, the company combines biochemistry and nanotechnology to create a wearable patch for real-time hormone monitoring, similar to glucose monitors. 

According to the company, this innovation could transform healthcare in areas like IVF, menopause, and testosterone replacement therapy, reducing the need for frequent blood tests, which are currently burdensome for many patients.

Level Zero Health is supported by a range of investors, including Redalpine, HAX (SOSV), Entrepreneur First London, Unruly Capital, Exceptional Ventures, Samos, Anorak, Springbank Collective, DTX, Black Jays, and Transpose Platform. 

The company has also secured funding from angel investors such as Aaron Styer, medical director at CCRM Fertility and Harvard Medical School associate professor; Joshua Klein, medical director at Extend Fertility and assistant professor at Icahn School of Medicine; and Charlie Bryant, CEO and co-founder of Simple Pharma.

Capital utilisation

Co-founder & CEO, Rustamova, says, “Our innovative remote monitoring technology marks an enormous leap forward in hormone testing, and this funding will enable us to bring this revolutionary solution to market.”

“This breakthrough in health technology has come about in a relatively short amount of time, but already we are seeing strong demand from customers who recognise the benefits of hormone monitoring not only because it allows patients to skip invasive and inconvenient lab tests, but also because it captures critical data inaccessible before.”

Although still in its early stages, Level Zero Health has built a strong customer pipeline. The company plans to use its funding for research and development, market-entry, and team expansion in the UK and US. 

While focusing on B2B clinical applications initially, it is also positioning itself for potential growth in B2C and the pharmaceutical sector.

Philip Kneis, an investor at Redalpine and board member of Level Zero Health, adds, “We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalised health management.”

Level Zero Health assembles top clinical advisory board

Level Zero Health has formed a top clinical advisory board, featuring experts such as Aaron Styer, medical director at CCRM Fertility and Harvard Medical School associate professor; Kelly Walker, a board-certified urologist and medical advisor at hims; and Joshua Klein, medical director at Extend Fertility and assistant professor at Icahn School of Medicine at Mount Sinai.

Aaron Styer MD, co-founding partner and medical director at CCRM Fertility Boston, says, “Improvements in healthcare delivery have been impacted by the limitations of existing devices and applications. This technological breakthrough by Level Zero Health will transform the clinician’s ability to manage and monitor hormonal-based diseases and treatments.”

“The technology has a myriad of applications across remote hormonal monitoring for fertility treatments and endocrine disorders. It will significantly expand patient access to care, reduce healthcare costs, and enable clinicians to change the paradigm of medical practice.”